Humboldt Holdings

Humboldt Therapeutics (operating as Humboldt Holdings, LLC) is a clinical-stage biotechnology company focused on developing innovative treatments for opioid use disorder (OUD) and chronic pain. The company's lead candidate, HTX-101, is a long-acting injectable formulation of buprenorphine designed to improve patient adherence and clinical outcomes compared to existing daily therapies. Humboldt's proprietary drug delivery platform aims to optimize the pharmacokinetic profiles of established therapeutic agents to address significant unmet needs in the central nervous system (CNS) space. Based in San Francisco, the company leverages its expertise in formulation science to create sustained-release versions of critical medications. Humboldt is a private entity dedicated to advancing its pipeline through clinical trials and potential strategic partnerships.